HOME >> BIOLOGY >> NEWS
Promising multi-strain HIV vaccine candidate emerges

BALTIMORE, Md.--AIDS researchers have developed a candidate vaccine strategy that, for the first time, demonstrates an ability to elicit antibodies that block the infection of multiple HIV virus strains -- an elusive scientific goal that has been pursued for a decade.

The candidate vaccine - still early in developmental stages at the Institute of Human Virology (IHV) -- is described in a report to appear during the week of Aug. 19-23 in the U.S. Proceedings in the National Academy of Sciences (PNAS). It is authored by Drs. Timothy Fouts, Anthony Devico, and colleagues at the IHV, a center of the University of Maryland Biotechnology Institute and affiliated with the University of Maryland Medical Center, and Dr. Ranajit Pal and colleagues at Advanced BioScience Laboratories, Inc. (ABL) in Kensington, Md.

One of the major challenges in developing an effective AIDS vaccine has long been the fact that the virus that causes AIDS, much like the influenza virus, exists as multiple strains that present many different faces to the immune system, say the authors. The surface of the AIDS virus, HIV, is coated with a protein called gp120 that has chemical features that vary from strain to strain. It has been difficult for researchers to find a single vaccine component that is able to generate antibodies that recognize the many forms of gp120 that exist in nature.

The IHV/ABL research team approached the problem by recognizing that all gp120 molecules have a shared characteristic that allows all HIV strains to bind a molecule on human target cells called CD4. Importantly, once gp120 forms a complex with CD4, it undergoes structural and chemical changes that reveal features shared by all HIV strains.

Taking advantage of this knowledge, the team produced artificial gp120-CD4 complexes that were chemically treated in order to glue or "crosslink" them together. The complexes were then used to generate antibodies in small animals and monkeys.'"/>

Contact: Gwen Fariss Newman
newmang@umbi.umd.edu
410-706-4616
University of Maryland Biotechnology Institute
19-Aug-2002


Page: 1 2 3

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising biomarker for melanoma is identified
5. Promising new therapies for deadly form of leukemia
6. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
7. SFU Spin-Off Company To Research Promising Antibacterial Agents
8. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
9. UNC-CH Researchers Develop Promising Heart Research Tool
10. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia
11. Promising Fatty Acid Research Leads To MS Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... FLINT, Mich. , Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... as a specialty pharmacy resource–user-centric, story-driven, knowledge-based and mobile-friendly. ... ... ... "The ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
Breaking Biology Technology:
Cached News: